Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Atrial fibrillation (AF) is a cardiac arrhythmia associated to aging, arterial hypertension, valve
disease and other heart disorders. 1 Atrial fibrillation is associated to an increased mortality …

Objective Nonvalvular atrial fibrillation (NVAF) is a risk factor for ischemic stroke and
systemic embolism. New oral anticoagulants are currently available. The objective of this …

Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …

BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

Background and objective Non-valvular atrial fibrillation (NVAF) increases the risk of
systemic thromboembolic events; therefore, anticoagulant treatment with vitamin K …

The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into clinical
practice represented a major change in the treatment of non-valvular atrial fibrillation …

Background and Purpose—The use of oral anticoagulant therapy for stroke prevention in
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …

Objective new oral anticoagulants (apixaban, dabigatran and rivaroxaban) are the newest
advance for stroke's risk reduction in atrial fibrillation. These are as effective as warfarin in …